Spiros Linardopoulos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5554255/publications.pdf

Version: 2024-02-01

49 papers	2,664 citations	201658 27 h-index	214788 47 g-index
49 all docs	49 docs citations	49 times ranked	4275 citing authors

#	Article	IF	Citations
1	CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells. British Journal of Cancer, 2021, 125, 966-974.	6.4	11
2	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. Blood Advances, 2020, 4, 1478-1491.	5.2	15
3	Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development. Methods in Molecular Biology, 2019, 1953, 33-42.	0.9	2
4	Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species. European Journal of Pharmaceutical Sciences, 2019, 139, 104899.	4.0	3
5	High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Molecular Cancer Therapeutics, 2019, 18, 1696-1707.	4.1	24
6	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer Discovery, 2018, 8, 498-515.	9.4	79
7	Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. Nature Communications, 2018, 9, 1044.	12.8	39
8	Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4-d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N²-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N⁸-neopentylpyrido[3,4-(BOS172722). Journal of Medicinal Chemistry, 2018, 61, 8226-8240.	6.4	24
9	Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis. Oncotarget, 2018, 9, 19525-19542.	1.8	27
10	Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy. British Journal of Cancer, 2017, 116, 1166-1176.	6.4	23
11	Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 2410-2421.	4.1	32
12	RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. British Journal of Cancer, 2017, 117, 954-964.	6.4	14
13	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. Journal of Medicinal Chemistry, 2016, 59, 3671-3688.	6.4	29
14	Aurora Kinase Inhibitors: Current Status and Outlook. Frontiers in Oncology, 2015, 5, 278.	2.8	221
15	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance. Cancer Research, 2015, 75, 3340-3354.	0.9	27
16	Aurora Kinase Inhibition: A New Light in the Sky?. Journal of Medicinal Chemistry, 2015, 58, 5186-5188.	6.4	9
17	7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4203-4209.	2.2	13
18	New therapeutic perspectives in <scp>CCDC</scp>6 deficient lung cancer cells. International Journal of Cancer, 2015, 136, 2146-2157.	5.1	41

#	Article	IF	Citations
19	APC/C is an essential regulator of centrosome clustering. Nature Communications, 2014, 5, 3686.	12.8	70
20	Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3469-3474.	2.2	5
21	Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1). Journal of Medicinal Chemistry, 2013, 56, 10045-10065.	6.4	72
22	Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells. Journal of Medicinal Chemistry, 2013, 56, 9122-9135.	6.4	70
23	Aurora A Kinase Regulates Mammary Epithelial Cell Fate by Determining Mitotic Spindle Orientation in a Notch-Dependent Manner. Cell Reports, 2013, 4, 110-123.	6.4	59
24	Tumour selective targeting of cell cycle kinases for cancer treatment. Current Opinion in Pharmacology, 2013, 13, 529-535.	3.5	65
25	Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development. Methods in Molecular Biology, 2013, 986, 97-104.	0.9	6
26	Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2012, 55, 8721-8734.	6.4	61
27	Sensitization of (colon) cancer cells to death receptor related therapies. Cancer Biology and Therapy, 2012, 13, 458-466.	3.4	4
28	Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia, 2012, 26, 1462-1470.	7.2	105
29	Abstract 889: Integration of centrosome-associated and kinase-related screens to identify centrosome amplification-related synthetic lethal interactions. , 2012, , .		0
30	The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and SensitizesMYCN-Amplified NeuroblastomaIn Vivo. Molecular Cancer Therapeutics, 2011, 10, 2115-2123.	4.1	79
31	Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia Research, 2011, 35, 1273-1275.	0.8	6
32	Functional Viability Profiles of Breast Cancer. Cancer Discovery, 2011, 1, 260-273.	9.4	134
33	Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.. , 2011, , .		3
34	Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate. Journal of Medicinal Chemistry, 2010, 53, 5213-5228.	6.4	80
35	Auroraâ€A expressing tumour cells are deficient for homologyâ€directed DNA double strandâ€break repair and sensitive to PARP inhibition. EMBO Molecular Medicine, 2010, 2, 130-142.	6.9	60
36	Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5988-5993.	2.2	30

#	Article	IF	Citations
37	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Modern Pathology, 2010, 23, 1334-1345.	5.5	61
38	A Cancer-associated Aurora A Mutant Is Mislocalized and Misregulated Due to Loss of Interaction with TPX2. Journal of Biological Chemistry, 2009, 284, 33177-33184.	3.4	40
39	The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis. Cell Cycle, 2007, 6, 3114-3131.	2.6	59
40	Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular Cancer Therapeutics, 2007, 6, 3147-3157.	4.1	65
41	Aurora-A Regulation of Nuclear Factor-ÎºB Signaling by Phosphorylation of IÎºBÎ±. Cancer Research, 2007, 67, 1689-1695.	0.9	92
42	Aurora kinase inhibition downregulates NF-ÎºB and sensitises tumour cells to chemotherapeutic agents. Biochemical and Biophysical Research Communications, 2007, 352, 220-225.	2.1	66
43	Hit generation and exploration: Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6567-6571.	2.2	78
44	Aurora-A kinase regulates NF-kappaB activity: lessons from combination studies. Journal of B U on, 2007, 12 Suppl 1, S67-70.	0.4	4
45	Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate, 2006, 66, 326-333.	2.3	138
46	The N-terminal domain of the Aurora-A Phe-31 variant encodes an E3 ubiquitin ligase and mediates ubiquitination of IÎºBÎ±. Human Molecular Genetics, 2006, 15, 3343-3350.	2.9	7
47	Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phenotype and Is Required for Thyroid Carcinoma Cell Proliferation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 928-935.	3.6	184
48	High-Throughput Screening Assay for Identification of Small Molecule Inhibitors of Aurora2/STK15 Kinase. Journal of Biomolecular Screening, 2004, 9, 391-397.	2.6	18
49	Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nature Genetics, 2003, 34, 403-412.	21.4	310